tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Thermo Fisher (TMO) and Atreca (BCEL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRNResearch Report), Thermo Fisher (TMOResearch Report) and Atreca (BCELResearch Report) with bullish sentiments.

BioMarin Pharmaceutical (BMRN)

SVB Securities analyst Joseph Schwartz reiterated a Buy rating on BioMarin Pharmaceutical yesterday and set a price target of $115.00. The company’s shares closed last Thursday at $79.28.

According to TipRanks.com, Schwartz ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -14.8% and a 26.3% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Mereo Biopharma Group Plc, and Crinetics Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioMarin Pharmaceutical with a $114.36 average price target, implying a 45.9% upside from current levels. In a report issued on May 12, Wedbush also reiterated a Buy rating on the stock with a $147.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Thermo Fisher (TMO)

Robert W. Baird analyst Catherine Ramsey Schulte reiterated a Buy rating on Thermo Fisher on May 18 and set a price target of $711.00. The company’s shares closed last Thursday at $550.74.

According to TipRanks.com, Schulte is a 5-star analyst with an average return of 16.7% and a 56.4% success rate. Schulte covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Twist Bioscience, and NanoString Tech.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Thermo Fisher with a $641.88 average price target, representing a 18.9% upside. In a report released yesterday, SVB Securities also maintained a Buy rating on the stock with a $640.00 price target.

Atreca (BCEL)

Robert W. Baird analyst Joel Beatty maintained a Buy rating on Atreca on May 18 and set a price target of $9.00. The company’s shares closed last Thursday at $1.69, close to its 52-week low of $1.56.

According to TipRanks.com, Beatty is a 1-star analyst with an average return of -0.5% and a 42.1% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, and BioMarin Pharmaceutical.

Atreca has an analyst consensus of Strong Buy, with a price target consensus of $17.40, representing a 923.5% upside. In a report issued on May 11, Brookline Capital Markets also reiterated a Buy rating on the stock with a $17.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BMRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed